Center-Authored Papers

Filters: Author is Shore, Neal D  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
S
Sonpavde G, Di Lorenzo G, Higano CS, Kantoff PW, Madan R, Shore ND.  2012.  The Role of Sipuleucel-T in Therapy for Castration-Resistant Prostate Cancer: A Critical Analysis of the Literature.. European urology. 61(4):639-647. Abstract
Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, Alumkal JJ, Higano CS, Chow Maneval E, Bandekar R et al..  2016.  Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.. European urology. Abstract
Shore ND, Crawford DE, Higano CS, Sartor O.  2016.  Advancing Treatment Strategies in Metastatic Castration-resistant Prostate Cancer: The Urologists Role.. Urology.
R
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ et al..  2015.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet. Oncology. 16(2):152-60. Abstract
Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PFA, Mainwaring P, Hainsworth JD et al..  2014.  Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302).. European urology. Abstract
Q
Quinn DI, Vaishampayan U, Higano CS, Lin DW, Shore ND, Beer TM.  2014.  Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.. Expert review of anticancer therapy. 14(1):51-61. Abstract
P
Parekh DJ, Punnen S, Sjoberg DD, Asroff SW, Bailen JL, Cochran JS, Concepcion R, David RD, Deck KB, Dumbadze I et al..  2014.  A Multi-institutional Prospective Trial in the USA Confirms that the 4Kscore Accurately Identifies Men with High-grade Prostate Cancer.. European urology. Abstract
C
Crawford DE, Shore ND, Petrylak DP, Higano CS, Ryan CJ.  2017.  Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility.. Therapeutic advances in medical oncology. 9(5):319-333. Abstract
Crawford DE, Stone NN, Yu EY, Koo PJ, Freedland SJ, Slovin SF, Gomella LG, Berger RE, Keane TE, Sieber P et al..  2014.  Challenges and Recommendations for Early Identification of Metastatic Disease in Prostate Cancer.. Urology. Abstract
Crawford DE, Higano CS, Shore ND, Hussain M, Petrylak DP.  2015.  Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.. The Journal of urology. 194(6):1537-47. Abstract
Crawford DE, Petrylak DP, Higano CS, Kibel AS, Kantoff PW, Small EJ, Shore ND, Ferrari A.  2015.  Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer.. The Canadian journal of urology. 22(6):8048-55. Abstract
A
Antonarakis ES, Kibel AS, Yu EY, Karsh LI, Elfiky A, Shore ND, Vogelzang NJ, Corman JM, Millard FE, Maher JC et al..  2016.  Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically-Recurrent Prostate Cancer: A Phase II Randomized Trial.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract